Literature DB >> 10515650

Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?

A Calin1, J P Nakache, A Gueguen, H Zeidler, H Mielants, M Dougados.   

Abstract

OBJECTIVE: Disease activity has been defined using a self-administered instrument, focusing on fatigue, axial pain, peripheral pain, enthesopathy and morning stiffness [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)]. This validated instrument is simple and takes 40 s to complete, but whether the index is an accurate expression of the component parts, or whether additional weighting would enhance its efficacy, is unclear.
METHODS: Four hundred and seventy-three patients with ankylosing spondylitis received placebo or active non-steroidal anti-inflammatory drug (NSAID) for 6 weeks, and changes between entry and completion were captured by BASDAI and the individual components. Principle component analysis (PCA) was used to explore the best combinations of variables in decreasing order of explained total dispersion and to assess whether a single sum (or algebraic expression) best defined disease activity status.
RESULTS: At entry, the correlation between BASDAI and the first axis was 0.99, 0.11 with the second, and zero thereafter. Data at study end and relating to change revealed a 100% correlation (R = 1) between the first axis and the sum, with zero for the remainder.
CONCLUSIONS: The data support BASDAI as being a valid and appropriate composite to define disease activity in ankylosing spondylitis. Developed as a simple sum of its components, BASDAI has excellent content validity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515650     DOI: 10.1093/rheumatology/38.9.878

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  38 in total

1.  Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

Authors:  J Braun; J Xiang; J Brandt; H Maetzel; H Haibel; P Wu; S Kohler; M Rudwaleit; S Siegert; A Radbruch; A Thiel; J Sieper
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  Intravenous pamidronate in treatment of non-steroidal anti-inflammatory drug-refractory ankylosing spondylitis.

Authors:  Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

4.  Employment perspectives of patients with ankylosing spondylitis.

Authors:  A M J Chorus; A Boonen; H S Miedema; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

5.  Evaluation of the impact of nursing clinics in the rheumatology services.

Authors:  Santiago Muñoz-Fernández; Ma Dolores Aguilar; Amparo Rodríguez; Raquel Almodóvar; Laura Cano-García; Luís Antonio Gracia; José A Román-Ivorra; J Ramón Rodríguez; Teresa Navío; Pablo Lázaro
Journal:  Rheumatol Int       Date:  2016-07-19       Impact factor: 2.631

6.  How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?

Authors:  Annelies Boonen; Désirée van der Heijde; Robert Landewé; Astrid van Tubergen; Herman Mielants; Maxime Dougados; Sjef van der Linden
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

7.  The international classification for functioning, disability and health. A challenge and a need for rheumatology.

Authors:  Annelies Boonen; Johannes J Rasker; Gerold Stucki
Journal:  Clin Rheumatol       Date:  2007-06-09       Impact factor: 2.980

8.  Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?

Authors:  Yuen Ling Elaine Au; Woon Sing Raymond Wong; Mo Yin Mok; Ho Yin Chung; Eric Chan; Chak Sing Lau
Journal:  Clin Rheumatol       Date:  2014-07-01       Impact factor: 2.980

9.  Comparison of the BASDAI and the miniBASDAI in assessing disease activity in patients with ankylosing spondylitis.

Authors:  Jinane Hakkou; Samira Rostom; Nawal Aissaoui; Kenza Berrada Ghezioul; Rachid Bahiri; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2011-10-12       Impact factor: 2.980

10.  The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis.

Authors:  Murat Karkucak; Erhan Capkin; Ahmet Alver; Ayse Akyuz; Abdulkadir Kiris; Emel Ak; Murat Topbas; Mehmet Tosun
Journal:  Clin Rheumatol       Date:  2009-12-11       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.